SYMBIOMIX THERAPEUTICS
Symbiomix is a late-stage, privately-held biopharmaceutical company developing innovative medicines for serious women’s health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world’s leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences, and HBM Partners. The Company’s lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next-generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.
SYMBIOMIX THERAPEUTICS
Industry:
Biopharma Biotechnology Medical Pharmaceutical
Founded:
2012-01-01
Address:
Newark, New Jersey, United States
Country:
United States
Website Url:
http://www.symbiomix.com
Total Employee:
11+
Status:
Active
Contact:
1(609) 722-7250
Total Funding:
47 M USD
Technology used in webpage:
SPF Apache Pound Sterling DMARC Japanese Yen Network Solutions DNS Mimecast Symantec Secure Site Confluence Networks Intermedia
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Rescindo Therapeutics
Rescindo Therapeutics is a drug development firm that offers discoveries and clinical translations.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Investors List
Eight Roads Ventures
Eight Roads Ventures investment in Venture Round - Symbiomix Therapeutics
F-Prime Capital
F-Prime Capital investment in Series A - Symbiomix Therapeutics
HBM Partners
HBM Partners investment in Series A - Symbiomix Therapeutics
Square 1 Bank
Square 1 Bank investment in Series A - Symbiomix Therapeutics
OrbiMed
OrbiMed investment in Series A - Symbiomix Therapeutics
F-Prime Capital
F-Prime Capital investment in Seed Round - Symbiomix Therapeutics
Official Site Inspections
http://www.symbiomix.com
- Host name: 208.91.197.27
- IP address: 208.91.197.27
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
